Drug Profile
KHK 6188
Alternative Names: KHK-6188Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kyowa Hakko Kirin
- Class Analgesics; Small molecules
- Mechanism of Action Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 18 Oct 2013 Discontinued - Phase-II for Neuropathic pain in Japan (PO)
- 11 Jun 2012 Phase-II clinical trials in Neuropathic pain in Japan (PO)
- 21 Feb 2012 Kyowa Hakko Kirin plans a phase II trial for Postherpetic neuralgia in Japan (NCT01544296)